Advanced search
Publication Cover
OncoTargets and Therapy Volume 16, 2023 - Issue
Submit an article Journal homepage
309
Views
2
CrossRef citations to date
0
Altmetric
CASE REPORT

A Refractory Case of CDKN2A/B Loss Metastatic Intrahepatic Cholangiocarcinoma Achieving a Partial Response After First-Line Treatment with Palbociclib

Weiming Fan1 Department of Biliary-Pancreatic Surgery, First People’s Hospital of Foshan, Foshan, People’s Republic of ChinaView further author information
,
Chuan Wang1 Department of Biliary-Pancreatic Surgery, First People’s Hospital of Foshan, Foshan, People’s Republic of ChinaView further author information
,
Xuefeng Zhong2 The Medical Department, 3D Medicines, Inc., Shanghai, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-2293-3202View further author information
ORCID Icon,
Yating Zheng2 The Medical Department, 3D Medicines, Inc., Shanghai, People’s Republic of ChinaView further author information
,
Tingting Chen2 The Medical Department, 3D Medicines, Inc., Shanghai, People’s Republic of ChinaView further author information
,
Mengli Huang2 The Medical Department, 3D Medicines, Inc., Shanghai, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0003-0169-7906View further author information
ORCID Icon &
Shuying Su1 Department of Biliary-Pancreatic Surgery, First People’s Hospital of Foshan, Foshan, People’s Republic of ChinaCorrespondence[email protected]
View further author information
 show all
Pages 23-29 | Received 09 Oct 2022, Accepted 24 Nov 2022, Published online: 19 Jan 2023

References

  • Kelley RK, Bridgewater J, Gores GJ, et al. Systemic therapies for intrahepatic cholangiocarcinoma. J Hepatol. 2020;72(2):353–363. doi:10.1016/j.jhep.2019.10.009
  • Sirica AE, Gores GJ, Groopman JD, et al. Intrahepatic cholangiocarcinoma: continuing challenges and translational advances. Hepatology. 2019;69:1803–1815. doi:10.1002/hep.30289
  • Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–1281. doi:10.1056/NEJMoa0908721
  • Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX. New horizons for precision medicine in biliary tract cancers. Cancer Discov. 2017;7:943–962. doi:10.1158/2159-8290.CD-17-0245
  • Lamarca A, Barriuso J, McNamara MG, Valle JW. Molecular targeted therapies: ready for “prime time” in biliary tract cancer. J Hepatol. 2020;73:170–185. doi:10.1016/j.jhep.2020.03.007
  • Roussel MF. The INK4 family of cell cycle inhibitors in cancer. Oncogene. 1999;18:5311–5317. doi:10.1038/sj.onc.1202998
  • Wiedemeyer WR, Dunn IF, Quayle SN, et al. Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. Proc Natl Acad Sci U S A. 2010;107:11501–11506. doi:10.1073/pnas.1001613107
  • Konecny GE, Winterhoff B, Kolarova T, et al. Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. Clin Cancer Res. 2011;17:1591–1602. doi:10.1158/1078-0432.CCR-10-2307
  • Young RJ, Waldeck K, Martin C, et al. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines. Pigment Cell Melanoma Res. 2014;27:590–600. doi:10.1111/pcmr.12228
  • Franco J, Witkiewicz AK, Knudsen ES. CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer. Oncotarget. 2014;5(15):6512–6525. doi:10.18632/oncotarget.2270
  • Tabrizian P, Jibara G, Hechtman JF, et al. Outcomes following resection of intrahepatic cholangiocarcinoma. HPB. 2015;17:344–351. doi:10.1111/hpb.12359
  • Park J, Kim MH, Kim KP, et al. Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study. Gut Liver. 2009;3:298–305. doi:10.5009/gnl.2009.3.4.298
  • Walker AJ, Wedam S, Amiri-Kordestani L, et al. FDA approval of palbociclib in combination with fulvestrant for the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer. Clin Cancer Res. 2016;22:4968–4972. doi:10.1158/1078-0432.CCR-16-0493
  • Clark AS, Karasic TB, DeMichele A, et al. Palbociclib (PD0332991)-A selective and potent cyclin-dependent kinase inhibitor: a review of pharmacodynamics and clinical development. JAMA Oncol. 2016;2:253–260. doi:10.1001/jamaoncol.2015.4701
  • Logan JE, Mostofizadeh N, Desai AJ, et al. PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity. Anticancer Res. 2013;33:2997–3004.
  • Pal SK, Ali SM, Ross J, Choueiri TK, Chung JH. Exceptional response to palbociclib in metastatic collecting duct carcinoma bearing a CDKN2A homozygous deletion. JCO Precis Oncol. 2017;1:1–5. doi:10.1200/PO.17.00017
  • Frisone D, Charrier M, Clement S, et al. Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss. Cancer Biol Ther. 2020;21:197–202. doi:10.1080/15384047.2019.1685291
  • Saqub H, Proetsch-Gugerbauer H, Bezrookove V, et al. Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9. Sci Rep. 2020;10:18489. doi:10.1038/s41598-020-75578-5
  • Sittithumcharee G, Suppramote O, Vaeteewoottacharn K, et al. Dependency of cholangiocarcinoma on cyclin D-dependent kinase activity. Hepatology. 2019;70:1614–1630. doi:10.1002/hep.30704
  • Al Baghdadi T, Halabi S, Garrett-Mayer E, et al. Palbociclib in patients with pancreatic and biliary cancer with CDKN2A alterations: results from the targeted agent and profiling utilization registry study. JCO Precis Oncol. 2019;3:1–8. doi:10.1200/PO.19.00124
  • Xu SF, Guo Y, Zhang X, et al. Somatic mutation profiling of intrahepatic cholangiocarcinoma: comparison between primary and metastasis tumor tissues. J Oncol. 2020;2020:5675020. doi:10.1155/2020/5675020

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.